Oral-mucosal administration of IFN-alpha potentiates immune response in mice.
We studied the effects of oral-mucosal administration of murine interferon-alpha (Mu-IFN-alpha) on immune responses and infection with vaccinia virus (VV) in mice. When Mu-IFN-alpha was administered to sheep red blood cell (SRBC)-sensitized mice for 4 or 5 days, Mu-IFN-alpha significantly enhanced delayed-type hypersensitivity (DTH) and antibody production, with maximum enhancement of each at 1 IU/body. To investigate the antiviral effect of oral-mucosal Mu-IFN-alpha, mice were infected with VV, and Mu-IFN-alpha was administered for 15 days. Pocks were observed in the tail skin of infected mice, and Mu-IFN-alpha at doses of 1, 10, and 100 IU/body significantly suppressed pock formation. Also, VV-specific cytotoxic T cells (CTL) were observed in the spleen from the same mice at 7 days after infection, and Mu-IFN-alpha enhanced CTL activity at doses above 1 IU/body. These results suggest that the oral-mucosal Mu-IFN-alpha may have potentiating effects on cellular and humoral immune responses, which may contribute to its effects against VV.
Biosciences Research Laboratory, Mochida Pharmaceutical Co., Ltd., Tokyo, Japan. ynagao@mochida.co.jp
Y
Y
Nagao
K
K
Yamashiro
N
N
Hara
Y
Y
Horisawa
K
K
Kato
A
A
Uemura
D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation; D000998:Antiviral Agents / Q000627:therapeutic use*; D006968:Hypersensitivity, Delayed / Q000276:immunology; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009061:Mouth Mucosa / Q000187:drug effects; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014615:Vaccinia / Q000188:drug therapy*
D000998:Antiviral Agents; D016898:Interferon-alpha